PCI Biotech: Mandatory notification regarding exercise and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PCI Biotech: Mandatory notification regarding exercise and trade of subscription rights and trade of shares

Oslo, December 21, 2016 - Overview of mandatory notification regarding exercise and trade of subscription rights and trade of shares. Management and the board of directors of PCI Biotech Holding ASA ("PCI Biotech" or "the Company") are all supportive to the share issue resolved by the extra ordinary general meeting 8 December 2016. In total the transactions disclosed herein leads to a net increase in shareholding by primary insiders of PCI Biotech of 91.549 shares and in addition other employees have a net increase in shareholdings of 10.856 shares. The following transactions are made:

1. Exercise of subscription rights and sale of shares today, 21 December 2016

This section details the exercise of subscription rights and, where relevant, sale of shares done to finance all or parts of the subscription rights exercised.

Per Walday, CEO, has subscribed for 29.542 new shares in the Company at a subscription price of NOK 7 per share by exercising 29.542 subscription rights in the Company's ongoing rights issue and has simultaneously sold a total of 10.000 shares at an average price of NOK 12.15 per share. After the transactions, Per Walday will have a total shareholding in the Company of 63.561 shares, 0 subscription rights in the rights issue and 25.000 unexercised stock options in relation to the Company's stock option scheme. For a total overview of holdings, see section 4.

Ronny Skuggedal, CFO, has subscribed for 10.066 new shares in the Company at a subscription price of NOK 7 per share by exercising 10.066 subscription rights in the Company's ongoing rights issue. After the transaction, Ronny Skuggedal will have a total shareholding in the Company of 25.066 shares, 0 subscription rights in the rights issue and 66.000 unexercised stock options in relation to the Company's stock option scheme. For a total overview of holdings, see section 4.

Anders Høgset, CSO, has subscribed for 32.198 new shares in the Company at a subscription price of NOK 7 per share by exercising 32.198 subscription rights in the Company's ongoing rights issue and has simultaneously sold a total of 18.800 shares at an average price of NOK 12.15 per share. After the transactions, Anders Høgset will have a total shareholding in the Company of 61.375 shares, 0 subscription rights in the rights issue and 17.000 unexercised stock options in relation to the Company's stock option scheme. For a total overview of holdings, see section 4.

Kristin Eivindvik, PD, has subscribed for 8.882 new shares in the Company at a subscription price of NOK 7 per share by exercising 8.882 subscription rights in the Company's ongoing rights issue and has simultaneously sold a total of 5.250 shares at an average price of NOK 12.15 per share. After the transactions, Kristin Eivindvik will have a total shareholding in the Company of 16.867 shares, 0 subscription rights in the rights issue and 24.500 unexercised stock options in relation to the Company's stock option scheme. For a total overview of holdings, see section 4.

The Board of Director's member, Christina Herder, has subscribed for 3.355 new shares in the Company at a subscription price of NOK 7 per share by exercising 3.355 subscription rights in the Company's ongoing rights issue. After the transaction, Christina Herder will hold a total shareholding in the Company of 8.355 shares and 0 subscription rights in the rights issue. For a total overview of holdings, see section 4.

In addition, the Chairman Hans Peter Bøhn subscribed for 33.556 new shares in the Company's ongoing rights issue at 14 December 2016 (the transaction was also disclosed 14 December 2016). After the transaction, Hans Peter Bøhn will have a total shareholding in the company of 83.556 shares and 0 subscription rights in the rights issue. Hans Peter Bøhn has previously entered into a guarantee agreement of NOK 1 000 000 in relation to the rights issue, and the exercise of subscription rights will, in compliance with the guarantee agreement, reduce the guarantee liability correspondingly. For a total overview of holdings, see section 4.

2. Sale of subscription rights today, 21 December 2016

Gaël L'Hévéder, CBDO, has sold 6.711 subscription rights at an average price of NOK 5.05 per subscription right. After the transaction, Gaël L'Hévéder holds 10.000 shares, 0 subscription rights in the rights issue and 91.000 unexercised stock options in relation to the Company's stock option scheme. For a total overview of holdings, see section 4.

3. Purchase of shares today, 21 December 2016

The board of Director's member Lars Viksmoen has purchased 4.000 shares in the Company at an average share price of NOK 12.15 per share. The transaction is made through his fully owned company, Stocken Invest AS, and the purchase is made from other primary insiders in the Company. After the transaction, Lars Viksmoen, holds a total of 4.000 shares in the Company. For a total overview of holdings, see section 4.

The board of Director's member Kjetil Taskén has purchased 4.000 shares in the Company at an average share price of NOK 12.15 per share. The transaction is made through his fully owned company, Kjetil Tasken AS, and the purchase is made from other primary insiders in the Company. After the transaction, Kjetil Tasken, holds a total of 4.000 shares in the Company. For a total overview of holdings, see section 4.

In addition, one employee has purchased 4.000 shares from primary insiders in the Company at an average share price of NOK 12.15 per share.

4. Overview new holdings per 21 December 2016

For a complete overview of new holdings after the transactions disclosed above and completion of the rights issue, please see attachment. In total the transactions disclosed herein leads to a net increase in shareholding by primary insiders of PCI Biotech of 91.549 shares and in addition other employees have a net increase in shareholdings of 10.856 shares.

For further information, please contact Ronny Skuggedal, CFO                rs@pcibiotech.no Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...b341d84017

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 120

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 65

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 46

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 100

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 143

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 139

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 75

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading

Top 5 Most Recently Viewed Articles

Twist Bioscience Set to Showcase Innovations at J.P. Morgan Event

Updated Category News Views 105

Twist Bioscience to Present at Renowned Healthcare Conference Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in the synthetic biology and genomics field, has announced an upcoming presentation at the annual J.P. Morgan Healthcare Conference. This significant event is slated for January, and it serves as a vital platform for the company to showcase its...

Continue Reading
Leidos Secures Major NSA Contract Worth $390 Million

Updated Category News Views 154

Leidos Wins $390 Million NSA Signals Intelligence Contract Leidos, a prominent player in the defense and technology sectors, has recently secured a significant contract to enhance the capabilities of the National Security Agency (NSA) in the field of signals intelligence (SIGINT). This contract, valued at $390 million, will span an initial year with four additional...

Continue Reading
Devin Shanahan's Strategic Innovations in Global Trade Adaptation

Updated Category News Views 165

Adapting to Global Trade Challenges In a rapidly changing trade landscape, Devin Shanahan, co-founder of the innovative consumer brand Funtazma, is leading thoughtful changes in supply chain management due to the growing impact of U.S.-China trade tensions. With a wealth of experience in scaling consumer brands through global sourcing, Shanahan has been pivotal in guiding...

Continue Reading
Animal Nutrition Chemicals Market Insights and Growth Prospects

Updated Category News Views 185

Animal Nutrition Chemicals Market Overview The rapidly evolving animal nutrition chemicals market is poised for remarkable growth. As the need for high-quality and nutritious animal feed continues to escalate, this sector is likely to see significant changes and expansion. Comprehensive analyses reveal a bright future as industry players adapt to shifting demands and...

Continue Reading
Investors Ensnared in Orthofix Securities Fraud Case Seek Justice

Updated Category News Views 49

Understanding the Orthofix Securities Fraud Case Recently, investors in Orthofix Medical Inc. were informed about a serious legal action involving alleged securities fraud. The Schall Law Firm, which advocates for shareholder rights, is leading a class action lawsuit that addresses the alleged missteps by Orthofix during a specific time frame. It’s important for...

Continue Reading